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1. INTRODUCTION {#jocd13035-sec-0006}
===============

There are two categories of aging process with intrinsic and extrinsic aging. The former is represented by internal factors as accompanied by genetic events, and the latter is related to external factors such as stress, radiation, pollution, and smoking.[1](#jocd13035-bib-0001){ref-type="ref"} Aging skin has features in changes in skin thickness, epidermal and dermal layer which appear as wrinkles, and structural abnormalities including degeneration of dermal elastic fibers.[2](#jocd13035-bib-0002){ref-type="ref"} Clinically, the skin becomes coarse, then thins, and becomes lax, showing sallowness, wrinkles, irregular hyperpigmentation, lentigines, and telangiectasias.[3](#jocd13035-bib-0003){ref-type="ref"}

As people grow older, they become interested in the condition of their skin.[4](#jocd13035-bib-0004){ref-type="ref"} Skin wrinkles are typical phenomena of aging with morphological changes in relation to dermal function with breakdown and generation of collagen.[5](#jocd13035-bib-0005){ref-type="ref"} Wrinkle researches have been developed with animal and in vitro models.[6](#jocd13035-bib-0006){ref-type="ref"} Keratinocytes release inflammatory cytokines including interleukin (IL)‐1, IL‐6, IL‐8, IL‐10, and tumor necrosis factor (TNF)‐α upon exposure to UV.[7](#jocd13035-bib-0007){ref-type="ref"} UVB‐induced cell damage leads to activation of reactive oxygen species (ROS)‐sensitive signaling pathways, such as the mitogen‐activated protein kinase (MAPK) pathway.[8](#jocd13035-bib-0008){ref-type="ref"} This pathway is an important mediator of inflammatory cytokine induction in response to UVB irradiation.[9](#jocd13035-bib-0009){ref-type="ref"}

Various cosmetics can inhibit skin wrinkles, distinct from drugs, which are used for a set period for the treatment of medical conditions.[10](#jocd13035-bib-0010){ref-type="ref"} It is important to secure the safety of cosmetics because they are routinely used for a long time.[11](#jocd13035-bib-0011){ref-type="ref"} The safety of skin applications is determined individually based on the ingredients used.[12](#jocd13035-bib-0012){ref-type="ref"} It is performed on the subjects who have normal skin, and the appearance of erythema, edema, swelling, and papules is evaluated by experts to determine product safety.[13](#jocd13035-bib-0013){ref-type="ref"}

The rhizomes of *Anemarrhena asphodeloides* Bunge (Liliaceae) have been used in traditional medicine as an antidiabetic, an antipyretic, and an antidepressant in China, Japan, and Korea. It is also used to treat febrile disease in clinical practice in China.[14](#jocd13035-bib-0014){ref-type="ref"}, [15](#jocd13035-bib-0015){ref-type="ref"} Various chemical constituents are reported to be present in *A asphodeloides*, among which timosaponin A‐III (TA‐III) has various pharmacological efficacy and is used as an antidiabetic, antipyretic, and antidepressive material in traditional medicine.[15](#jocd13035-bib-0015){ref-type="ref"}, [16](#jocd13035-bib-0016){ref-type="ref"}, [17](#jocd13035-bib-0017){ref-type="ref"}, [18](#jocd13035-bib-0018){ref-type="ref"} In previous research, TA‐III inhibits metastasis.[19](#jocd13035-bib-0019){ref-type="ref"} However, there is no study to protect photoaging caused by UVB.

In order to identify potential antiwrinkle agent, various compounds from *A asphodeloides* were evaluated in HaCaT cells. In skin clinical trials, the safety of TA‐III and the effect of inhibiting skin wrinkles were examined and confirmed for use as cosmetics for skin wrinkle prevention.

2. MATERIALS AND METHODS {#jocd13035-sec-0007}
========================

2.1. Isolation process {#jocd13035-sec-0008}
----------------------

Timosaponin A‐III (TA‐III; Figure [1](#jocd13035-fig-0001){ref-type="fig"}) was isolated as previously described.[20](#jocd13035-bib-0020){ref-type="ref"}

![Chemical structure of timosaponin A‐III, isolated from *Anemarrhena asphodeloides*](JOCD-19-423-g001){#jocd13035-fig-0001}

2.2. UVB irradiation and cell viability assay {#jocd13035-sec-0009}
---------------------------------------------

An immortalized nontumorigenic human keratinocyte cell line (HaCaT) (1 × 10^4^) was seeded into 96‐well culture plates and exposed to 20 mJ/cm^2^ of UVB in the presence or absence of TA‐III for 24 hr Immediately after UVB irradiation, cell viability was assessed by incubation with 3‐(4,5‐dimethylthiazol‐2‐yl)‐5‐(3‐carboxymethoxyphenyl)‐2‐(4‐sulfophenyl)‐2H‐tetrazolium, inner salt (MTS) for 1 hr and measuring its reduction to formazan, according to the manufacturer\'s instructions; samples were assayed at 490 nm using a microplate spectrophotometer (Molecular Devices).

2.3. Analysis of MMP‐1 secretions by ELISA {#jocd13035-sec-0010}
------------------------------------------

After UVB irradiation, MMP‐1 levels in the culture media of HaCaT cells (5 × 10^4^) were determined using human total MMP‐1 ELISA kits according to the manufacturer\'s instructions. HaCaT cells were seeded and treated with extracts and various compounds (timosaponin A‐III, timosaponin B, timosaponin B‐II, anemarsaponin B, anemarsaponin E, and timosaponin C) from *A asphodeloides*. To perform quantification of MMP‐1 secretions induced by UVB exposure, the culture supernatant was measured by colorimetric analysis.

2.4. Quantitative real‐time polymerase chain reaction (qRT‐PCR) assays {#jocd13035-sec-0011}
----------------------------------------------------------------------

Total RNA was extracted from each sample using TRIzol (Invitrogen). qRT‐PCR was performed using TaqMan assays (Applied Biosystems) specific for TIMP, IL‐1β, IL‐8, and TNF‐α (TIMP1; Hs00171558_m1, IL‐1β; Hs00174097_m1, IL‐8; Hs00174103_m1, TNF‐α; Hs01113624_g1) on a QuantStudio™ 6 Flex Real‐Time PCR system. Each sample was assayed in triplicate, and relative mRNA expression levels were calculated using the ΔΔCt method and normalized to the β‐actin mRNA level in each sample.

2.5. Clinical safety test {#jocd13035-sec-0012}
-------------------------

### 2.5.1. Human subjects and methods {#jocd13035-sec-0013}

A total of 30 subjects were recruited and conducted in accordance with the guideline of Ministry of Food and Drug Safety in Korea based on Declaration of Helsinki, as appropriate. Timosaponin A‐III (TA‐III) was prepared as described previously.[20](#jocd13035-bib-0020){ref-type="ref"} An agent containing 0.25% of TA‐III (Table [1](#jocd13035-tbl-0001){ref-type="table"}) was applied as a test solution (test group). The patch was left on the testing area for 48 h containing 20 μL of the test solution, and upon removal of the patch, the testing area was marked with a skin marker. Each testing area was observed after 30 min and 24 hr The patch test has been done including positive (0.5% SLS, sodium lauryl sulfate) and negative (Squalane) controls.

###### 

Percent composition (w/w) of the formulations applied to skin

  Components             Vehicle group (%)   TA‐III group (%)
  ---------------------- ------------------- ------------------
  Water                  84.80               84.55
  Dipropylene glycol     5.00                5.00
  Disodium EDTA          0.02                0.02
  Phenoxyethanol         0.30                0.30
  Carbomer               0.20                0.20
  Glyceryl stearate      1.50                1.50
  Sorbitan stearate      0.50                0.50
  Polysorbate 60         1.50                1.50
  Cetearyl alcohol       1.50                1.50
  Cetyl ethylhexanoate   2.50                2.50
  Sodium hydroxide       0.080               0.08
  Water                  2.00                2.00
  Fragrant               0.10                0.10
  TA‐III                 ---                 0.25
  Distilled water        100                 100
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### 2.5.2. Limitations and assessment criteria {#jocd13035-sec-0014}

While the patches were in place, the subjects were instructed not to let the testing area (back) come into contact with water. Observations were made 30 min and 24 hr after patch removal, and skin reactions were assessed according to the criteria of the Frosch & Kligman method[21](#jocd13035-bib-0021){ref-type="ref"} and the guidelines of the Personal Care Product Council (PCPC; Table [2](#jocd13035-tbl-0002){ref-type="table"}).[22](#jocd13035-bib-0022){ref-type="ref"}

###### 

Clinical standard photographs of visual assessment for human patch test

  Description                                 After 30 min                        After 24 h
  ------------------------------------------- ----------------------------------- -----------------------------------
  Slight erythema, either spotty or diffuse   ![](JOCD-19-423-g009.jpg "image")   ![](JOCD-19-423-g010.jpg "image")
  Moderate uniform erythema                   ![](JOCD-19-423-g011.jpg "image")   ![](JOCD-19-423-g012.jpg "image")
  Intense erythema with edema                 ![](JOCD-19-423-g013.jpg "image")   ![](JOCD-19-423-g014.jpg "image")
  Intense erythema with edema and vesicle     ![](JOCD-19-423-g015.jpg "image")   ![](JOCD-19-423-g016.jpg "image")
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### 2.5.3. Calculation of results {#jocd13035-sec-0015}

The average reactivity at 48 and 72 hr was calculated using the equation below, and the average reactivity to each individual solution was determined according to the Frosch & Kligman criteria (Table [3](#jocd13035-tbl-0003){ref-type="table"}).$$\text{Response} = \frac{\Sigma\left( {\text{Grade} \times \text{No.}\,\text{of}\,\text{Responders}} \right)}{4\mspace{6mu}\left( {\text{Maximum}\,\text{grade}} \right) \times n\left( {\text{Total}\,\text{Subjects}} \right)} \times 100 \times 1/2$$

###### 

Human primary irritation index for cosmetic products[12](#jocd13035-bib-0012){ref-type="ref"}

  Range of response    Criteria
  -------------------- ----------
  0.00 ≤ *R* \< 0.87   Slight
  0.87 ≤ *R* \< 2.42   Mild
  2.42 ≤ *R* \< 3.44   Moderate
  3.44 ≤ *R*           Severe

John Wiley & Sons, Ltd

2.6. Antiwrinkle clinical trials {#jocd13035-sec-0016}
--------------------------------

### 2.6.1. Patients and methods {#jocd13035-sec-0017}

The study was conducted in accordance with the intent and purpose of good clinical practice regulations as described in Korean Good Clinical Practice (KGCP) and/or the Declaration of Helsinki, as appropriate. The study protocol was approved by DERMAPRO Ltd., Institutional Review Board (1‐220777‐A‐N‐02, Protocol approval No.: 1‐220777‐A‐N‐02‐DICN15088). Furthermore, this study protocol was followed functional cosmetic guideline of Ministry of Food and Drug Safety in Korea. This study has been uploaded to <http://cris.nih.go.kr/cris/index.jsp> (identifier KCT0002223) from National Research Institute of Health. The subjects of this study were women aged 30‐65 years, who met the inclusion criteria. Subjects who had started to develop wrinkles or who already had wrinkles, as defined by functional cosmetic guideline criteria, were explained the purpose and procedure of this study. Written consent was obtained from subjects who were interested in this study in advance and was informed of expected efficacy and potential adverse events.

For this study, 21 women between the ages of 43 and 55 were selected. Subjects who were beginning to form or had already formed wrinkles, according to the SOP of the DermaPro Institute of Dermatological Sciences, were targeted. Those with the intention to participate were given study‐participation consent forms to fill out and were enrolled in the study. They were healthy without acute and chronic diseases including skin diseases, who voluntarily signed the written consent after hearing an explanation of the purpose and details of the study, and who would be able for follow‐up assessments during the testing period.

The subjects were informed that no other functional cosmetics or drugs should be used with the test product. Subjects were told that they could use basic cosmetic products in addition to the test product, including toners with no functional ingredients, moisturizers, foundation, powder, cosmetic pencils, and lipstick. Subjects were asked to apply sunscreen products before going outside. The subjects were asked not to apply any colored make‐up prior to assessments. The Guidelines for the Evaluation of the Effectiveness of Functional Cosmetic Products (2003, 2005), cosmetics displays, and the Testing Methods Guidelines for the Validation of Ads (2013) were used to select study subjects. The test product contained 0.25% of TA‐III (Table [1](#jocd13035-tbl-0001){ref-type="table"}) was applied to crow\'s feet region twice a day during the 12 weeks.

### 2.6.2. Visual assessment of skin wrinkles {#jocd13035-sec-0018}

Wrinkles around the eyes were independently assessed under specific lighting conditions. At each assessment, wrinkles were graded into 10 stratified grades in 0.5‐point increments; the mean of the two values chosen by the two evaluators was used in the statistical analysis (Table [4](#jocd13035-tbl-0004){ref-type="table"}).

###### 

Visual assessment using a modified version of Danielle\'s criteria

  Grade[\*](#jocd13035-note-0001){ref-type="fn"}   Description criteria
  ------------------------------------------------ ------------------------------------------------------------------------------------------------
  0                                                There are no skin wrinkles, and skin texture is delicate
  1                                                Thin wrinkles on the skin are starting to become visible
  2                                                Thin wrinkles on the skin are visible
  3                                                There are many thin wrinkles on the skin, and moderate wrinkles are starting to become visible
  4                                                Moderate wrinkles on the skin are visible
  5                                                There are moderate wrinkles, but deep wrinkles are not visible
  6                                                There are many moderate wrinkles on the skin, and deep wrinkles are starting to become visible
  7                                                Deep wrinkles on the skin are visible
  8                                                There are many deep wrinkles on the skin
  9                                                There are excessively numerous deep wrinkles on the skin

^\*^Wrinkles were assessed in 0.5‐unit increments.
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### 2.6.3. Evaluation of skin wrinkle parameters using skin replicas {#jocd13035-sec-0019}

To evaluate skin wrinkles, skin replica images were analyzed using a Visioline^®^ VL650 (C+K) at each assessment session. This device captures images by transmitting light to the replica at an angle of 35°; it is equipped with a fabricated SILFLO replica that is installed in its frame. The images were marked with green shadows and automatically quantified; they were then analyzed for five wrinkle parameters: skin roughness (Rt), maximum roughness (Rm), average roughness (Rz), smoothness depth (Rp), and arithmetic average roughness (Ra; Table [5](#jocd13035-tbl-0005){ref-type="table"}).

###### 

Diagram and definition of wrinkle parameters

  Parameters                          Description criteria
  ----------------------------------- ---------------------------------
  ![](JOCD-19-423-g017.jpg "image")   Skin roughness Rt
  ![](JOCD-19-423-g018.jpg "image")   Maximum roughness Rm
  ![](JOCD-19-423-g019.jpg "image")   Average roughness Rz
  ![](JOCD-19-423-g020.jpg "image")   Smoothness depth Rp
  ![](JOCD-19-423-g021.jpg "image")   Arithmetic average roughness Ra

John Wiley & Sons, Ltd

### 2.6.4. Subject questionnaire {#jocd13035-sec-0020}

After 4, 8, and 12 weeks of using the product, subjects were instructed to complete a product efficacy questionnaire that used a 5‐point scale: 1 = I do not agree at all, 2 = I do not agree, 3 = There is no difference, 4 = I agree, 5 = I strongly agree. After 12 weeks of using the product, participants completed a product usability questionnaire that also used a 5‐point scale: 1 = It is not effective at all; 2 = It is not effective; 3 = It is normal; 4 = It is effective; 5 = It is very effective; the questionnaire was analyzed for positive answers (scores of 4, 5).

2.7. Statistical analysis {#jocd13035-sec-0021}
-------------------------

All data were analyzed for statistical significance using the SPSS^®^ Package Program (IBM). For the visual assessment, the evaluators were considered reliable when the intraclass correlation coefficient was \>0.8, and the mean value was analyzed. The normality of the distribution was tested using kurtosis and skewness, and prehomogeneity was verified using a paired *t* test. A repeated‐measures analysis of variance (ANOVA) was used to determine interdependence (or reciprocal action) between repeated measurements, as well as to compare groups. Statistical analysis was done in terms of comparison between both groups (test vs control group).

The efficacy questionnaire was evaluated using the Mann‐Whitney *U* test to compare the two groups in terms of nonparametric mean values; the product usability questionnaire was evaluated using the chi‐squared test. Statistical significance was defined as a *P‐*value \< 0.05.

3. RESULTS {#jocd13035-sec-0022}
==========

3.1. Photoprotective effects of TA‐III on HaCaT cells {#jocd13035-sec-0023}
-----------------------------------------------------

UVB irradiation reduced cell viability to 49.6% as compared with the control level. However, incubating the cells with 0.1 µmol/L of TA‐III prior to irradiation, cell viability was maintained at 100.4% of the control level (Figure [2](#jocd13035-fig-0002){ref-type="fig"}).

![Effects of TA‐III on cell viability in HaCaT cells after UVB irradiation. HaCaT cells were pretreated with TA‐III at concentrations indicated for 24 h, followed by UVB irradiation. Data are reported as percentages. ^\#\#\#\#^ *P* \< 0.0001 for the comparison with the control group and \*\*\*\**P* \< 0.0001 for the comparison with the vehicle group](JOCD-19-423-g002){#jocd13035-fig-0002}

3.2. MMP‐1 inhibition by TA‐III {#jocd13035-sec-0024}
-------------------------------

To find out active compound in *A asphodeloides*, extracts and various compounds (timosaponin A‐III, timosaponin B, timosaponin B‐II, anemarsaponin B, anemarsaponin E, and timosaponin C) from *A asphodeloides* were evaluated in terms of skin wrinkle reduction as measured by MMP‐1 level in UVB‐treated cells. MMP‐1 levels were increased by UVB irradiation (Figure [3](#jocd13035-fig-0003){ref-type="fig"}). Among them, TA‐III showed strong activity on MMP‐1 inhibition. Also, TA‐III was isolated as major compound in *A asphodeloides*.

![TA‐III attenuated UVB‐induced effects on MMP‐1 expression in HaCaT cells. A: *Anemarrhena asphodeloides* extracts and various compounds (B: timosaponin A‐III, C: timosaponin B, D: timosaponin B‐II, E: anemarsaponin B, F: anemarsaponin E, and G: timosaponin C) treated with HaCaT cells for 24 h before UVB irradiation. Concentration of *A asphodeloides* extracts was µg/mL, and other compounds of concentrations were µmol/L. ^\#^ *P* \< 0.05 for the comparison with the control group and \**P* \< 0.05 for the comparison with the vehicle group](JOCD-19-423-g003){#jocd13035-fig-0003}

3.3. Effects of TA‐III on TIMP and inflammatory cytokines {#jocd13035-sec-0025}
---------------------------------------------------------

The mRNA levels of TIMP were measured by RT‐PCR after UVB irradiation of HaCaT cells. The level of TIMP was decreased after UVB irradiation, as compared to the control group (Figure [4](#jocd13035-fig-0004){ref-type="fig"}A). In results of mRNA expression, TA‐III increased TIMP mRNA levels as compared with the UVB‐irradiated cells.

![TA‐III treatment attenuated UVB‐induced effects on TIMP and pro‐inflammatory cytokine expression levels in HaCaT cells. (A) TIMP, (B) IL‐1β, (C) IL‐8, and (D) TNF‐α, mRNA levels were determined by qRT‐PCR analysis. \*\*\**P* \< 0.001, \*\**P* \< 0.01, and \**P* \< 0.05 for the comparison with the vehicle group](JOCD-19-423-g004){#jocd13035-fig-0004}

The expression of pro‐inflammatory cytokine mRNA transcripts was investigated in TA‐III‐treated cells. According to the result in Figure [4](#jocd13035-fig-0004){ref-type="fig"}(B‐D), IL‐1β, IL‐8, and TNF‐α mRNA levels were increased; however, TA‐III reversed this phenomenon. This suggested that photoprotective effect of TA‐III is based on anti‐inflammatory activity on UVB‐irradiated cells.

3.4. Subjects included in the skin safety test {#jocd13035-sec-0026}
----------------------------------------------

A total of 30 individuals participated in safety test. The mean age of the subjects was 42.1 ± 5.2 years, with the oldest being 50 years old and the youngest being 27 years old. The skin characteristics of the study subjects were examined through surveys, and the results are presented in Table [6](#jocd13035-tbl-0006){ref-type="table"}. During the study period, no skin reactions to the test solution (TA‐III) were observed (Table [7](#jocd13035-tbl-0007){ref-type="table"}).

###### 

Skin characteristics of subjects (n = 30)

  Items                            Classification                    Frequency (n)   Percentage (%)
  -------------------------------- --------------------------------- --------------- ----------------
  Skin type                        Dry skin                          13              43.33
  Normal skin                      11                                36.67           
  Oily skin                        0                                 0.00            
  Dry to oily skin                 6                                 20.00           
  Problem skin                     0                                 0.00            
  Irritability                     Yes                               3               10.00
  No                               27                                90.00           
  Stinging                         Yes                               0               0.00
  No                               30                                100.00          
  Side effects by cosmetics        Yes                               0               0.00
  No                               30                                100.00          
  Allergy                          Food allergy                      0               0.00
  Metal allergy                    0                                 0.00            
  Photoallergy                     0                                 0.00            
  Other allergy                    0                                 0.00            
  No                               30                                100.00          
  Skin diseases                    Acne                              0               0.00
  Atopy                            0                                 0.00            
  Hair loss                        1                                 3.33            
  Extra skin diseases              0                                 0.00            
  No                               29                                96.67           
  Tight feeling                    Yes                               0               0.00
  No                               30                                100.00          
  Taking supplements               Taking oriental herb medicines    0               0.00
  Taking nutrients                 6                                 20.00           
  Taking extra supplements         0                                 0.00            
  No                               24                                80.00           
  Smoking                          No                                30              100.00
  Less than 10 pieces              0                                 0.00            
  More than 10 pieces              0                                 0.00            
  Menstrual cycle                  Within 1 wk before menstruation   8               26.67
  During menstruation              3                                 10.00           
  Within 1 wk after menstruation   6                                 20.00           
  The others                       13                                43.33           

John Wiley & Sons, Ltd

###### 

Results of human skin primary irritation test (n = 30)

  No   Test material      No. of responder   48 h   72 h   Reaction grade                                             
  ---- ------------------ ------------------ ------ ------ ---------------- ----- ----- ----- ----- ----- ----- ----- -----
  1    TA‐III             0                  ---    ---    ---              ---   ---   ---   ---   ---   0.0   0.0   0.0
  2    Negative control   0                  ---    ---    ---              ---   ---   ---   ---   ---   0.0   0.0   0.0

John Wiley & Sons, Ltd

3.5. Skin characteristics of subjects for antiwrinkle test {#jocd13035-sec-0027}
----------------------------------------------------------

A total of 23 women aged 43‐55 years were included in this test. Two subjects dropped out (No. 4 and No. 12) for personal reasons; the clinical trial was conducted with 21 subjects. After finishing the clinical evaluation, the questionnaire was used to determine the characteristics of the subjects participating in clinical trial as shown in Table [8](#jocd13035-tbl-0008){ref-type="table"}.

###### 

Skin condition of volunteers by skin physiological factors (n = 21)

  Items                     Classification   Frequency (N)   Percentage (%)
  ------------------------- ---------------- --------------- ----------------
  Hydration                 Sufficient       0               0.00
  Normal                    13               61.90           
  Deficient                 8                38.10           
  Sebum                     Glossy           1               4.76
  Normal                    15               71.43           
  Deficient                 5                23.81           
  Surface                   Smooth           3               14.29
  Normal                    15               71.43           
  Rough                     3                14.29           
  Thickness                 Thin             3               14.29
  Normal                    14               66.67           
  Thick                     4                19.05           
  Duration of UV exposure   Less than 1 h    10              47.62
  1‐3 h                     10               47.62           
  More than 3 h             1                4.76            
  Sleeping hours            Less than 5 h    2               9.52
  5‐8 h                     17               80.95           
  More than 8 h             2                9.52            
  Smoking                   No               21              100.00
  Less than 10 pieces       0                0.00            
  More than 10 pieces       0                0.00            
  Irritability              Yes              1               4.76
  No                        20               95.24           
  Stinging                  Yes              0               0.00
  No                        21               100.00          
  Adverse reaction          Yes              0               0.00
  No                        21               100.00          

John Wiley & Sons, Ltd

3.6. Visual assessment {#jocd13035-sec-0028}
----------------------

In comparison within groups, wrinkles around the eyes were significantly ameliorated after both 8 and 12 weeks in the test group (*P* \< 0.01, Table [9](#jocd13035-tbl-0009){ref-type="table"}). In the control group, wrinkle reduction was shown after 12 weeks (*P* \< 0.01, Table [9](#jocd13035-tbl-0009){ref-type="table"}). In comparison between groups, the test group (TA‐III) showed significant wrinkle reduction after 12 weeks (*P* \< 0.01, Figure [5](#jocd13035-fig-0005){ref-type="fig"}).

###### 

Statistical analysis of visual assessment after application of the test and control groups

  Group         Week     N      Mean[a](#jocd13035-note-0002){ref-type="fn"}   SD     SEM           *P*‐value[b](#jocd13035-note-0003){ref-type="fn"}
  ------------- -------- ------ ---------------------------------------------- ------ ------------- ---------------------------------------------------
  TA‐III (A)    Before   21     5.21                                           1.09   0.24          ---
  4             21       5.19   1.10                                           0.24   0.162         
  8             21       5.08   1.09                                           0.24   0.008\*\*     
  12            21       4.93   1.03                                           0.23   0.000\*\*\*   
  Control (B)   Before   21     5.10                                           1.09   0.24          ---
  4             21       5.10   1.09                                           0.24   ---           
  8             21       5.02   1.07                                           0.23   0.083         
  12            21       4.98   1.03                                           0.23   0.009\*\*     

Decrement of the mean value represents decrease in wrinkle.

Significantly different at \*\**P* \< 0.01, \*\*\**P* \< 0.001 compared with before treatment.
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![Changes in visual assessment following 12 consecutive weeks of application of the product (TA‐III) and control groups (mean ± SEM, \*\**P* \< 0.01, \*\*\**P* \< 0.001 vs before treatment, ^††^ *P* \< 0.01 vs control group)](JOCD-19-423-g005){#jocd13035-fig-0005}

3.7. Analysis of wrinkle parameters using skin replicas {#jocd13035-sec-0029}
-------------------------------------------------------

### 3.7.1. Comparisons within groups (4, 8, and 12 weeks) {#jocd13035-sec-0030}

In the test group (TA‐III), Rt, Rm, and Ra were significantly reduced after 4, 8, and 12 weeks of product use, while Rz was significantly reduced after 8 and 12 weeks of product use and Rp was significantly reduced after 12 weeks of product use (*P* \< 0.01). In the control group, Rt, Rm, and Rz were significantly reduced after 8 and 12 weeks of product use (*P* \< 0.05; Table [10](#jocd13035-tbl-0010){ref-type="table"}, Figure [6](#jocd13035-fig-0006){ref-type="fig"}A--E).

###### 

Statistical analysis of skin wrinkle parameter following application of the test and control groups

  Parameters    Group        Week     N       Mean[a](#jocd13035-note-0004){ref-type="fn"}   SD            SEM    *P*‐value[b](#jocd13035-note-0005){ref-type="fn"}
  ------------- ------------ -------- ------- ---------------------------------------------- ------------- ------ ---------------------------------------------------
  Rt            TA‐III (A)   Before   21      63.27                                          9.53          2.08   ---
  4             21           62.22    9.61    2.10                                           0.002\*\*            
  8             21           60.82    9.77    2.13                                           0.000\*\*\*          
  12            21           58.86    9.38    2.05                                           0.000\*\*\*          
  Control (B)   Before       21       62.73   9.29                                           2.03          ---    
  4             21           62.42    9.16    2.00                                           0.408                
  8             21           61.72    9.03    1.97                                           0.010\*              
  12            21           60.68    8.63    1.88                                           0.000\*\*\*          
  Rm            TA‐III (A)   Before   21      57.68                                          8.85          1.93   ---
  4             21           56.51    8.77    1.91                                           0.003\*\*            
  8             21           55.12    8.85    1.93                                           0.000\*\*\*          
  12            21           53.02    8.38    1.83                                           0.000\*\*\*          
  Control (B)   Before       21       57.17   8.48                                           1.85          ---    
  4             21           56.58    8.25    1.80                                           0.294                
  8             21           55.79    7.87    1.72                                           0.016\*              
  12            21           55.17    7.81    1.71                                           0.000\*\*\*          
  Rz            TA‐III (A)   Before   21      42.78                                          6.80          1.48   ---
  4             21           42.09    7.29    1.59                                           0.104                
  8             21           41.07    6.51    1.42                                           0.000\*\*\*          
  12            21           39.30    6.42    1.40                                           0.000\*\*\*          
  Control (B)   Before       21       42.48   5.99                                           1.31          ---    
  4             21           41.81    6.24    1.36                                           0.177                
  8             21           41.23    6.24    1.36                                           0.022\*              
  12            21           40.39    5.85    1.28                                           0.000\*\*\*          
  Rp            TA‐III (A)   Before   21      35.54                                          6.06          1.32   ---
  4             21           35.26    6.31    1.38                                           0.599                
  8             21           34.67    6.36    1.39                                           0.066                
  12            21           33.50    6.38    1.39                                           0.000\*\*\*          
  Control (B)   Before       21       34.92   5.94                                           1.30          ---    
  4             21           35.35    5.82    1.27                                           0.333                
  8             21           34.59    5.44    1.19                                           0.397                
  12            21           34.08    5.18    1.13                                           0.102                
  Ra            TA‐III (A)   Before   21      7.00                                           1.32          0.29   ---
  4             21           6.69     1.42    0.31                                           0.008\*\*            
  8             21           6.62     1.28    0.28                                           0.003\*\*            
  12            21           6.38     1.28    0.28                                           0.000\*\*\*          
  Control (B)   Before       21       6.69    0.95                                           0.21          ---    
  4             21           6.53     0.93    0.20                                           0.326                
  8             21           6.60     1.05    0.23                                           0.537                
  12            21           6.61     1.09    0.24                                           0.570                

Decrement of the mean value represents decrease in wrinkle.

Significantly different at \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001 compared with before treatment.

John Wiley & Sons, Ltd

![Evaluation of skin wrinkle parameters using replica. A, Changes in skin roughness (Rt) following 12 consecutive weeks of application of the test (TA‐III) and control groups. B, Changes in maximum roughness (Rm) following 12 consecutive weeks of application of the test (TA‐III) and control groups. C, Changes in average roughness (Rz) following 12 consecutive weeks of application of the test (TA‐III) and control groups. D, Changes in smoothness depth (Rp) following 12 consecutive weeks of application of the test (TA‐III) and control groups. E, Changes in arithmetic average roughness (Ra) following 12 consecutive weeks of application of the test (TA‐III) and control groups (mean ± SEM, \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001 vs before treatment, ^†^ *P* \< 0.05, ^††^ *P* \< 0.01, ^†††^ *P* \< 0.001 vs control group)](JOCD-19-423-g006){#jocd13035-fig-0006}

### 3.7.2. Comparison between groups (control group and test group) {#jocd13035-sec-0031}

In the test group (TA‐III), Rt was significantly improved in the test group compared with the control group after 4, 8, and 12 weeks of product use; Rm, Rz, and Ra were significantly improved in the test group compared with the control group after 12 weeks of product use (*P* \< 0.05; Table [11](#jocd13035-tbl-0011){ref-type="table"}, Figure [6](#jocd13035-fig-0006){ref-type="fig"}A--E).

###### 

Statistical analysis of skin wrinkle parameter between the test and control groups (*P*‐value)

  Parameters   Group             4 wk[a](#jocd13035-note-0006){ref-type="fn"}   8 wk[a](#jocd13035-note-0006){ref-type="fn"}   12 wk[a](#jocd13035-note-0006){ref-type="fn"}
  ------------ ----------------- ---------------------------------------------- ---------------------------------------------- -----------------------------------------------
  Rt           Test vs Control   0.049\*                                        0.006\*\*                                      0.000\*\*\*
  Rm           Test vs Control   0.308                                          0.079                                          0.000\*\*\*
  Rz           Test vs Control   0.974                                          0.440                                          0.014\*
  Rp           Test vs Control   0.202                                          0.436                                          0.062
  Ra           Test vs Control   0.420                                          0.128                                          0.006\*\*

Significantly different at \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001 compared with the control group.

John Wiley & Sons, Ltd

3.8. Subject questionnaire {#jocd13035-sec-0032}
--------------------------

### 3.8.1. Product efficacy questionnaire {#jocd13035-sec-0033}

Among all participants, 76%‐86% of subjects in both the test and control groups responded positively to the items "Increase of skin moisture" and "Improvement of skin softness" after 8 and 12 weeks. Also, 48%‐62% of subjects in both the test and control groups responded positively to the item "Improvement of skin glossiness," "Improvement of skin elasticity," and "Decrease of skin wrinkle" after 8 and 12 weeks; this did not constitute a significant difference (Table [12](#jocd13035-tbl-0012){ref-type="table"} and Figure [7](#jocd13035-fig-0007){ref-type="fig"}).

###### 

Results of positive answers in self‐assessment for efficacy (n = 21)

  Items                            Week   TA‐III group (A)   Control group (B)   *P‐*value           
  -------------------------------- ------ ------------------ ------------------- ----------- ------- -------
  Increase of skin moisture        4      11                 52.38               8           38.10   0.390
  8                                17     80.95              17                  80.95       0.781   
  12                               18     85.71              16                  76.19       0.306   
  Improvement of skin softness     4      15                 71.43               11          52.38   0.248
  8                                17     80.95              16                  76.19       0.743   
  12                               18     85.71              17                  80.95       0.483   
  Improvement of skin glossiness   4      11                 52.38               11          52.38   0.877
  8                                11     52.38              11                  52.38       0.879   
  12                               11     52.38              10                  47.62       0.672   
  Improvement of skin elasticity   4      11                 52.38               10          47.62   0.672
  8                                13     61.90              12                  57.14       0.774   
  12                               12     57.14              12                  57.14       1.000   
  Decrease of skin wrinkle         4      6                  28.57               7           33.33   0.742
  8                                11     52.38              10                  47.62       0.760   
  12                               11     52.38              12                  57.14       0.759   

N (Frequency) = Number of positive answers (4, Agree \~ 5, Strongly agree); % (Percentage) = Number of positive answers/Total number of subjects (21) × 100.

John Wiley & Sons, Ltd

![Comparative sensorial profile of the test (TA‐III) and control groups for efficacy (positive answers, %)](JOCD-19-423-g007){#jocd13035-fig-0007}

### 3.8.2. Product usability questionnaire {#jocd13035-sec-0034}

In both the test (TA‐III) and control groups, 48%‐62% and 43%‐62% of subjects, respectively, responded positively to the items "color," "viscosity," "absorptivity," and "satisfaction," but there was no significant difference between the groups (Table [13](#jocd13035-tbl-0013){ref-type="table"} and Figure [8](#jocd13035-fig-0008){ref-type="fig"}).

###### 

Result of positive answers in self‐questionnaires for usability (n = 21)

  Items          TA‐III group (A)   Control group (B)   *P‐*value           
  -------------- ------------------ ------------------- ----------- ------- -------
  Color          13                 61.90               10          47.62   0.352
  Scent          7                  33.33               6           28.57   0.939
  Viscosity      10                 47.62               9           42.86   0.990
  Absorption     12                 57.14               9           42.86   0.643
  Satisfaction   13                 61.90               13          61.90   0.978

N (Frequency) = Number of positive answers (4, Good \~ 5, Very good); % (Percentage) = Number of positive answers/Total number of subjects (21) × 100.

John Wiley & Sons, Ltd

![Comparative sensorial profile of the test (TA‐III) and control groups for usability (positive answers, %)](JOCD-19-423-g008){#jocd13035-fig-0008}

4. DISCUSSION {#jocd13035-sec-0035}
=============

Skin aging may result from cumulative exposure to environmental factors related to wrinkle formation.[23](#jocd13035-bib-0023){ref-type="ref"} Aging over time is a natural process caused by internal physiological factors that affect the skin similarly to other organs, leading to formation of relatively slight wrinkle.[24](#jocd13035-bib-0024){ref-type="ref"} By contrast, photoaging is correlated with exposure to the UV radiation in sunlight, which strongly contributes to a premature aging phenotype.[25](#jocd13035-bib-0025){ref-type="ref"}

Skin elasticity is reduced by the extracellular matrix degeneration with aging, and it is the most common feature of skin aging.[26](#jocd13035-bib-0026){ref-type="ref"} Wrinkles are formed by the breakdown of extracellular matrix such as collagen and elastin.[27](#jocd13035-bib-0027){ref-type="ref"} The complex mechanism such as collagen degradation and inhibition of new collagen production results in wrinkle formation in the dermis.[28](#jocd13035-bib-0028){ref-type="ref"}

Timosaponin A‐III (TA‐III) is present as one of the major chemical constituents in *A asphodeloides* rhizomes, and it is reported to have various biological effects.[29](#jocd13035-bib-0029){ref-type="ref"}, [30](#jocd13035-bib-0030){ref-type="ref"} In this research, we confirmed the photoprotective activity of TA‐III and compounds against UVB damage on skin cells.

MMPs and TIMPs are playing a role in the regulation of collagen metabolism.[31](#jocd13035-bib-0031){ref-type="ref"} MMPs produced by UVB exposure cause collagen degradation or inhibition of collagen synthesis, resulting in weak skin connective tissue.[32](#jocd13035-bib-0032){ref-type="ref"}, [33](#jocd13035-bib-0033){ref-type="ref"} We have already evaluated similar saponins such as *A asphodeloides* extracts and various compounds (timosaponin A‐III, timosaponin B, timosaponin B‐II, anemarsaponin B, anemarsaponin E, and timosaponin C). Among them, timosaponin A‐III showed strong activity on MMP‐1 inhibition. Also, TA‐III was isolated as major compound in *A asphodeloides* which means cost effective for cosmetic development. The photoprotective properties of TA‐III were measured in terms of the significant reduction in MMP‐1 and an increase in TIMP‐1.

Keratinocyte induces the NF‐κB pathway and inflammatory cytokines when exposed to UVB. These are associated with skin inflammatory responses.[34](#jocd13035-bib-0034){ref-type="ref"} Cytokines such as IL‐1β are known to stimulate the expression level of MMP‐1 in fibroblasts.[35](#jocd13035-bib-0035){ref-type="ref"} The qRT‐PCR analyses showed that TA‐III attenuated the UVB‐induced production of pro‐inflammatory cytokine mRNAs in HaCaT cells, including IL‐1β, IL‐8, and TNF‐α. This study demonstrated that exposure to UVB upregulated pro‐inflammatory cytokines and MMPs. The expression of inflammatory cytokines was increased by UVB irradiation in HaCaT cells which decreased the cell viability, but this phenomenon was suppressed by TA‐III.

In further study of clinical trials, the clinical safety of an agent containing 0.25% of TA‐III for use on human skin was performed. In comparison between groups, there was a significant difference in wrinkle parameters measured by replica at different time points. Furthermore, replica analysis in comparison between the control and test groups, Rt was significantly improved in the test group compared with the control group after 4, 8, and 12 weeks of product use; Rm, Rz, and Ra showed significant difference in the test group compared with the control group after 12 weeks of product use (*P* \< 0.05).

Safety and toxicity are important considerations for cosmetic products, as application of the product to the skin could lead to systemic exposure, resulting in adverse localized effects such as irritation, sensitization, or photoreactions.[11](#jocd13035-bib-0011){ref-type="ref"} Currently, a variety of naturally occurring agents that have antiaging effects are being used in skin care products.[36](#jocd13035-bib-0036){ref-type="ref"}, [37](#jocd13035-bib-0037){ref-type="ref"} In general, the effectiveness of cosmetics is assessed by clinical trial experts and wrinkle assessment is considered a primary endpoint.[38](#jocd13035-bib-0038){ref-type="ref"}, [39](#jocd13035-bib-0039){ref-type="ref"} According to skin safety results in this study, no dermatological problems were observed in subjects participating in clinical trial. In conclusion, TA‐III attenuated UVB‐induced skin damage and daily application of TA‐III for 12 weeks significantly reduced signs of facial aging by limiting wrinkle formation.

ETHICAL APPROVAL {#jocd13035-sec-0036}
================
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Research funding was provided by the Korea Institute of Oriental Medicine (K15301).
